InvestSMART

Dimerix Limited (ASX:DXB)

ALERT: Price-sensitive ASX Announcement for DXB
Current share price for DXB : $0.245 -0.05 (-16.95%)+
Announcement
Release
20 Aug 2026 9:13AM
Price at Release
$0.295
Full Release
download
Summary
Dimerix Limited, an Australian clinical-stage biopharmaceutical company focusing on kidney disease treatments, has received a US$10 million (~A$14.1 million) upfront payment from Everest Medicines as part of a licensing agreement. Everest has acquired the exclusive rights to develop and commercialize DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea, and Southeast Asia. This agreement is part of a broader strategy in which Dimerix has secured five regional partnerships, potentially generating up to A$1.9 billion in milestone payments alongside royalty income from net sales. Dimerix remains entitled to further success-based payments and continues to explore additional licensing opportunities for unpartnered regions. The company is also advancing its Phase 3 study, ACTION3, for DMX-200, and plans to initiate a Phase 2 trial for DMX-652. Dimerix's pipeline aims to address significant unmet needs in renal indications.
Key Points
  • Dimerix received US$10 million from Everest Medicines.
  • Everest gets rights to commercialize DMX-200 in Asia.
  • Dimerix has potential for A$1.9 billion in milestone payments.
  • Partnerships secured with five regional partners.
  • Ongoing licensing discussions for unpartnered regions.
  • Phase 3 study for DMX-200 and Phase 2 trial for DMX-652 in progress.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.